Dermata Therapeutics (Dermata Therapeutics) Beginning Cash Position : $7.44 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Beginning Cash Position?

Dermata Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was $7.44 Mil.

Dermata Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 ($8.44 Mil) to Dec. 2023 ($6.63 Mil) but then increased from Dec. 2023 ($6.63 Mil) to Mar. 2024 ($7.44 Mil).

Dermata Therapeutics's annual Beginning Cash Position increased from Dec. 2021 ($0.53 Mil) to Dec. 2022 ($10.80 Mil) but then declined from Dec. 2022 ($10.80 Mil) to Dec. 2023 ($6.24 Mil).

Dermata Therapeutics Beginning Cash Position Historical Data

The historical data trend for Dermata Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics Beginning Cash Position Chart

Dermata Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

1.18

1.99

0.53

10.80

6.24

Dermata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial													6.24	8.77	8.44	6.63	7.44

Dermata Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Dermata Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130

Website

https://www.dermatarx.com

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Executives

Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl	10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K.	officer: Chief Financial Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher	director	C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale	director	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga	director	C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott	director	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley	officer: Chief Financial Officer	SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E	officer: Senior VP	10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler	director	1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo	officer: Senior VP, Development	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc	10 percent owner	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130